TW202246318A - 犬抗體恆定區中之突變 - Google Patents

犬抗體恆定區中之突變 Download PDF

Info

Publication number
TW202246318A
TW202246318A TW111104187A TW111104187A TW202246318A TW 202246318 A TW202246318 A TW 202246318A TW 111104187 A TW111104187 A TW 111104187A TW 111104187 A TW111104187 A TW 111104187A TW 202246318 A TW202246318 A TW 202246318A
Authority
TW
Taiwan
Prior art keywords
igg
constant domain
canine
cdata
ser
Prior art date
Application number
TW111104187A
Other languages
English (en)
Chinese (zh)
Inventor
亨利 坎普斯
珊卓拉 賴托
莉莎 柏格倫
Original Assignee
美商碩騰服務公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商碩騰服務公司 filed Critical 美商碩騰服務公司
Publication of TW202246318A publication Critical patent/TW202246318A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW111104187A 2021-01-28 2022-01-28 犬抗體恆定區中之突變 TW202246318A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163142774P 2021-01-28 2021-01-28
US63/142,774 2021-01-28

Publications (1)

Publication Number Publication Date
TW202246318A true TW202246318A (zh) 2022-12-01

Family

ID=80786846

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111104187A TW202246318A (zh) 2021-01-28 2022-01-28 犬抗體恆定區中之突變

Country Status (15)

Country Link
US (1) US20240059777A1 (https=)
EP (2) EP4284825A2 (https=)
JP (1) JP2024505072A (https=)
KR (1) KR20230136604A (https=)
CN (1) CN116802205A (https=)
AU (1) AU2022214843A1 (https=)
CA (1) CA3207285A1 (https=)
CL (2) CL2023002202A1 (https=)
CO (1) CO2023009994A2 (https=)
EC (1) ECSP23057156A (https=)
IL (1) IL304522A (https=)
MX (1) MX2023008785A (https=)
PE (1) PE20231919A1 (https=)
TW (1) TW202246318A (https=)
WO (1) WO2022165067A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
WO2022165067A2 (en) 2021-01-28 2022-08-04 Zoetis Services Llc Mutations in canine antibody constant regions
CN119968390A (zh) * 2022-09-02 2025-05-09 硕腾服务有限责任公司 猪抗体突变体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2022165067A2 (en) 2021-01-28 2022-08-04 Zoetis Services Llc Mutations in canine antibody constant regions

Also Published As

Publication number Publication date
WO2022165067A2 (en) 2022-08-04
EP4284825A2 (en) 2023-12-06
EP4512416A3 (en) 2025-06-18
JP2024505072A (ja) 2024-02-02
CL2024001562A1 (es) 2024-08-23
CN116802205A (zh) 2023-09-22
IL304522A (en) 2023-09-01
CO2023009994A2 (es) 2023-08-09
WO2022165067A3 (en) 2022-09-22
ECSP23057156A (es) 2023-08-31
EP4512416A2 (en) 2025-02-26
US20240059777A1 (en) 2024-02-22
CL2023002202A1 (es) 2024-01-12
AU2022214843A1 (en) 2023-07-20
CA3207285A1 (en) 2022-08-04
AU2022214843A9 (en) 2024-05-16
KR20230136604A (ko) 2023-09-26
MX2023008785A (es) 2023-12-14
PE20231919A1 (es) 2023-11-28

Similar Documents

Publication Publication Date Title
CN116897053B (zh) 含抗tslp抗体的药物组合物
CN113474372B (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
TW202246318A (zh) 犬抗體恆定區中之突變
TW202204404A (zh) 貓抗體變異體
CN114685660A (zh) 抗cldn18.2抗体及其制备方法和应用
TW202300526A (zh) 針對ｇｄｆ－１５的抗體
KR20150081289A (ko) 항체 또는 항체 조성물의 제조 방법
TW202233687A (zh) 貓抗體恆定區中之突變
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
RU2739208C2 (ru) Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение
TW202229337A (zh) 犬抗體變異體
KR20230104611A (ko) 항-cd94 항체 및 이의 사용 방법
TW202222838A (zh) 一種抗ceacam5的人源化抗體及其製備方法和用途
TWI814094B (zh) 貓抗體變異體
AU2021209282B2 (en) Anti-Sars-Cov-2 Neutralizing Antibodies
KR20240004694A (ko) 항체
TWI915520B (zh) 含抗tslp抗體的藥物組合物
KR20180129791A (ko) 혈 중에서 합토글로빈에 결합하여 다가의 면역 복합체를 형성하는 항체를 유효 성분으로 하는 자기 면역 질환 치료제
RU2858900C2 (ru) Варианты кошачьих антител
RU2855157C1 (ru) Мутации в константных областях антител кошек
RU2840969C1 (ru) Варианты кошачьих антител
RU2846726C1 (ru) Варианты собачьих антител
CN115667297B (zh) 结合il6r的抗体及其用途
RU2847183C1 (ru) Варианты собачьих антител
CN113135994B (zh) 一种激活型抗ox40抗体、生产方法及应用